Early research (Phase 1)Ended earlyNCT04800822What this trial is testingPF-07284892 in Participants With Advanced Solid TumorsWho this might be right forSolid Tumor Pfizer 53
Large-scale testing (Phase 3)Looking for participantsNCT07491445What this trial is testingStudy of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaWho this might be right forPancreatic CancerPancreatic Cancer MetastaticPDAC+5 more Revolution Medicines, Inc. 900
Early research (Phase 1)Active Not RecruitingNCT05907304What this trial is testingAssess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsWho this might be right forAdvanced or Metastatic Solid Tumors Erasca, Inc. 86
Testing effectiveness (Phase 2)Study completedNCT01277406What this trial is testing4SC-201 (Resminostat) in Advanced Colorectal CarcinomaWho this might be right forAdvanced Colorectal Carcinoma 4SC AG 17
Testing effectiveness (Phase 2)Study completedNCT05340621What this trial is testingNAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)Who this might be right forRAS MutationNRAS Gene MutationMelanoma OnKure, Inc. 36
Early research (Phase 1)Study completedNCT02906059What this trial is testingStudy of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal CancerWho this might be right forMetastatic Colorectal Cancer NYU Langone Health 7
Testing effectiveness (Phase 2)WithdrawnNCT03266159What this trial is testingA Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid TumorsWho this might be right forSolid Tumours GlaxoSmithKline
Not applicableActive Not RecruitingNCT03908788What this trial is testingDetection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) TherapyWho this might be right forMetastatic Colorectal Cancer Institut du Cancer de Montpellier - Val d'Aurelle 130
Not applicableUnknownNCT03524677What this trial is testingMutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative DiagnosisWho this might be right forPancreatic Cancer University of Roma La Sapienza 50
Testing effectiveness (Phase 2)UnknownNCT06206096What this trial is testingPD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRCWho this might be right forColorectal CancerRAS MutationColorectal Neoplasms+1 more Chinese PLA General Hospital 40
Large-scale testing (Phase 3)Looking for participantsNCT06226857What this trial is testingOther Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal CancerWho this might be right forColorectal NeoplasmsChemotherapy EffectMolecular Sequence Variation City Clinical Oncology Hospital No 1 355
Testing effectiveness (Phase 2)UnknownNCT04010552What this trial is testingNalirinox Neo-pancreas RAS Mut ctDNA StudyWho this might be right forResectable Pancreatic Ductal Adenocarcinoma Fundación de investigación HM 20
Not applicableUnknownNCT02502656What this trial is testingRAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal CancerWho this might be right forColorectal Cancer Association des Gastroentérologues Oncologues 425
Testing effectiveness (Phase 2)Ended earlyNCT04198818What this trial is testingEvaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced TumorsWho this might be right forAdvanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more Haihe Biopharma Co., Ltd. 37
Testing effectiveness (Phase 2)Looking for participantsNCT06922591What this trial is testingStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsWho this might be right forPDACPDAC - Pancreatic Ductal AdenocarcinomaNSCLC+5 more Tango Therapeutics, Inc. 183
Testing effectiveness (Phase 2)UnknownNCT05640726What this trial is testingThe First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard TherapyWho this might be right forRectal Cancer Fujian Cancer Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07622550What this trial is testingA Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal CanceWho this might be right forMetastatic Colorectal Cancer (CRC) Jiangsu Cancer Institute & Hospital 80
Testing effectiveness (Phase 2)Study completedNCT01116271What this trial is testingStudy of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With ColorecWho this might be right forColorectal Cancer AstraZeneca 32
Early research (Phase 1)Study completedNCT03317119What this trial is testingTrametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by SurgeryWho this might be right forMetastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Carcinoma+22 more City of Hope Medical Center 26
Early research (Phase 1)Ended earlyNCT02049801What this trial is testingMEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaWho this might be right forAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)+12 more Bruno C. Medeiros 1